Barcelona, February 27, 2026 – Catalonia.health participated this week in the fourth edition of the "Next Health: Life Sciences Innovation" conference series, co-organised with EY, focused on analysing how the Health & Life Sciences sector is generating tangible impact in sustainability. The event brought together experts from leading companies to share concrete examples of transformation and advances in this strategic area.

The technology center Eurecat, a Catalonia.health member, has incorporated a new technology called Olink® that analyzes up to 92 proteins simultaneously and accelerates the obtaining of results in advanced analysis of biological samples for the development of new products and services in sectors such as health, biotechnology, nutrition, and food.

The Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Nephrology Service of Hospital Germans Trias and the spin-off Debios Diagnostics, all three members of Catalonia.health, are driving the PROMORFI project, a translational innovation initiative aimed at improving the detection and monitoring of chronic kidney disease through new non-invasive diagnostic tools.

Nema Health, a biotechnology company specialized in personalized immunotherapies for cancer treatment and a Catalonia.health member, has closed its first seed funding round. The operation totals €1.06 million, comprising a capital increase of €730,000 and a grant of €335,000 awarded by the CDTI's NEOTEC program (2025 call).

D-Sight, a clinical-stage spin-off from the Vall d'Hebron Research Institute (VHIR) and a Catalonia.health member, has secured €2 million in a new funding round led by Clave Capital, the company's main investor, to accelerate its clinical development plan in neuroprotective therapies for ocular diseases.

Catalonia.health has formalized the renewal of its Board of Directors and appointed Eva García Ramos as the new president of the organization at the General Assembly held in L'Hospitalet de Llobregat.

The University of Barcelona, a Catalonia.health member, has presented the strategic project VISI-ON-BRAIN (Cutting-edge Human In Vitro and In Silico Biomedical Tools on Brain Disorders), a European training and research program with €4.5 million in funding that connects UB with the best research centers in Europe.

Zymvol, a biotechnology company and a member of Catalonia.health, has announced a strategic collaboration with Olon, a global CDMO and generic manufacturer, to accelerate the adoption of biocatalysis as a scalable manufacturing solution for the pharmaceutical industry.

Medichem Solutions S.L., a subsidiary of Medichem and a member of Catalonia.health, has announced a strategic collaboration with Breckenridge Pharmaceutical, Inc., a U.S.-based generic pharmaceutical company and subsidiary of Towa International.

Devicare, a leading pharmaceutical company in the field of urology and a member of Catalonia.health, has announced the acquisition of IP-6 International, Inc., a renowned North American nutritional supplement company and manufacturer of the IP6 Gold® brand. This operation represents Devicare's first acquisition outside Spain and constitutes a significant milestone in its international growth strategy.